Mitochondrial dysfunction plays a pivotal role in Alzheimer’s disease (AD), even before signs of AD pathology are evident. Our previous research has shown that oxygen treatment can improve cognitive function in AD model mice. To address whether oxygen treatment is beneficial to mitochondrial biology, we analyzed differential expressions of hippocampal mitochondrial proteins in AD model mice given supplementary oxygen. Numerous respiratory chain, Kreb’s cycle, and glycolysis proteins were upregulated significantly after oxygen treatment, suggesting that oxygen therapy can alleviate mitochondrial damage. Furthermore, the treatment was associated with decreased expressions of some AD biomarkers, suggesting oxygen treatment to be a potential therapy for AD.
YaoJ, IrwinRW, ZhaoL, NilsenJ, HamiltonRT, BrintonRD (2009) Mitochondrial bioenergetic deficit precedes Alzheimer’s pathology in female mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A106, 14670–14675.
4.
SwerdlowRH, BurnsJM, KhanSM (2014) The Alzheimer’s disease mitochondrial cascade hypothesis: Progress and perspectives. Biochim Biophys Acta1842, 1219–1231.
5.
SwerdlowRH, KhanSM (2004) A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease. Med Hypotheses63, 8–20.
6.
RheinV, BaysangG, RaoS, MeierF, BonertA, Müller-SpahnF, EckertA (2009) Amyloid-beta leads to impaired cellular respiration, energy production and mitochondrial electron chain complex activities in human neuroblastoma cells. Cell Mol Neurobiol29, 1063–1071.
7.
KeilU, BonertA, MarquesCA, ScherpingI, WeyermannJ, StrosznajderJB, Muller-SpahnF, HaassC, CzechC, PradierL, MullerWE, EckertA (2004) Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J Biol Chem279, 50310–50320.
8.
RheinV, SongX, WiesnerA, IttnerLM, BaysangG, MeierF, OzmenL, BluethmannH, DroseS, BrandtU, SavaskanE, CzechC, GotzJ, EckertA (2009) Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer’s disease mice. Proc Natl Acad Sci U S A106, 20057–20062.
9.
EckertA, NisbetR, GrimmA, GotzJ (2014) March separate, strike together–role of phosphorylated TAU in mitochondrial dysfunction in Alzheimer’s disease. Biochim Biophys Acta1842, 1258–1266.
SchulzKL, EckertA, RheinV, MaiS, HaaseW, ReichertAS, JendrachM, MüllerWE, LeunerK (2012) A new link to mitochondrial impairment in tauopathies. Mol Neurobiol46, 205–216.
12.
BrownWR, ThoreCR (2011) Review: Cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol37, 56–74.
13.
YagerJY, WrightS, ArmstrongEA, JahrausCM, SaucierDM (2006) The influence of aging on recovery following ischemic brain damage. Behav Brain Res173, 171–180.
14.
Chris PeersHAP, BoyleJohn P. (2007) Hypoxia and Alzheimer’s disease. Essays Biochem43, 153–164.
15.
WangH, WangY, HongX, LiS, WangY (2016) Quantitative proteomics reveals the mechanism of oxygen treatment on lenses of Alzheimer’s disease model mice. J Alzheimers Dis54, 275–286.
16.
RossiS, ZanierER, MauriI, ColumboA, StocchettiN (2001) Brain temperature, body core temperature, and intracranial pressure in acute cerebral damage. J Neurol Neurosurg Psychiatry71, 448–454.
17.
YinF, SanchetiH, PatilI, CadenasE (2016) Energy metabolism and inflammation in brain aging and Alzheimer’s disease. Free Radic Biol Med100, 108–122.
18.
JrPW, ParksJ, FilleyCM, KleinschmidtdemastersBK (1995) Electron transport chain defects in Alzheimer’s disease brain. Neurology45, 599–600.
19.
WallaceDC (2013) A mitochondrial bioenergetic etiology of disease. J Clin Invest123, 1405–1412.
20.
MaurerI, ZierzS, MöllerHJ (2000) A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol Aging21, 455–462.
21.
BirkAV, ChaoWM, BrackenC, WarrenJD, SzetoHH (2014) Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. Br J Pharmacol171, 2017–2028.
22.
WatsonJD (2014) Type 2 diabetes as a redox disease. Lancet383, 841–843.
23.
MastersCL, SelkoeDJ (2012) Biochemistry of amyloid beta-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med2, a006262.
24.
VoisineC, PedersenJS, MorimotoRI (2010) Chaperone networks: Tipping the balance in protein folding diseases. Neurobiol Dis40, 12–20.
25.
TamagnoE, ParolaM, BardiniP, PicciniA, BorghiR, GuglielmottoM, SantoroG, DavitA, DanniO, SmithMA, PerryG, TabatonM (2005) Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J Neurochem92, 628–636.
GuglielmottoM, AragnoM, AutelliR, GilibertoL, NovoE, ColombattoS, DanniO, ParolaM, SmithMA, PerryG, TamagnoE, TabatonM (2009) The up-regulation of BACE1 mediated by hypoxia and ischemic injury: Role of oxidative stress and HIF1α. J Neurochem108, 1045–1056.
28.
TamagnoE1, GuglielmottoM, AragnoM, BorghiR, AutelliR, GilibertoL, MuracaG, DanniO, ZhuX, SmithMA, PerryG, JoDG, MattsonMP, TabatonM (2008) Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor. J Neurochem104, 683–695.
29.
StockburgerC, GoldVA, PallasT, KolesovaN, MianoD, LeunerK, MüllerWE (2014) A cell model for the initial phase of sporadic Alzheimer’s disease. J Alzheimers Dis42, 395–411.
30.
HuYY, HeSS, WangXC, DuanQH, KhatoonS, IqbalK, Grundke-IqbalI, WangJZ (2002) Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci Lett320, 156–160.
31.
ZetterbergH (2016) Neurofilament light: A dynamic cross-disease fluid biomarker for neurodegeneration. Neuron91, 1–3.
32.
BaciogluM, MaiaLF, PreischeO, SchelleJ, ApelA, KaeserSA, SchweighauserM, EningerT, LambertM, PilottoA, ShimshekDR, NeumannU, KahlePJ, StaufenbielM, NeumannM, MaetzlerW, KuhleJ, JuckerM (2016) Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron91, 56–66.
33.
HeY, HuaY, LiuW, HuH, KeepRF, XiG (2009) Effects of cerebral ischemia on neuronal hemoglobin. J Cereb Blood Flow Metab29, 596–605.
34.
ChuangJY, LeeCW, ShihYH, YangT, YuL, KuoYM (2012) Interactions between amyloid-beta and hemoglobin: Imlications for amyloid plaque formation in Alzheimer’s disease. PLoS One7, e33120.
35.
DaulatzaiMA (2013) Death by a thousand cuts in Alzheimer’s disease: Hypoxia–the prodrome. Neurotox Res24, 216–243.
36.
FangH, ZhangLF, MengFT, DuX, ZhouJN (2010) Acute hypoxia promote the phosphorylation of tau via ERK pathway. Neurosci Lett474, 173–177.
37.
PlutaR, KockiJ, Ułamek-KoziołM, PetniakA, Gil-KulikP, JanuszewskiS, BoguckiJ, JabłońskiM, BrzozowskaJ, Furmaga-JabłońskaW, Bogucka-KockaA, CzuczwarSJ (2016) Discrepancy in expression of β-secretase and amyloid-β medial temporal lobe cortex following transient global brain ischemia. J Alzheimers Dis51, 1023–1031.
